Advertisement

Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Manual for Adrenocortical Carcinoma

  • Sarah B. Fisher
  • Mouhammed A. Habra
  • Yi-Ju Chiang
  • Si-Yuan Wu
  • Paul H. Graham
  • Elizabeth G. Grubbs
  • Jeffrey E. Lee
  • Nancy D. PerrierEmail author
Original Scientific Report

Abstract

Background

The American Joint Committee on Cancer 8th edition staging manual for adrenocortical carcinoma (ACC) redefines T stage to include large vessel invasion (T4, previously undescribed) and restricts stage IV to those with distant metastases. We evaluated the prognostic power of the 8th edition.

Methods

Patients with ACC treated between January 1, 2000, and December 31, 2015, were identified. Overall survival (OS) was compared using Kaplan–Meier and Cox proportional hazard models.

Results

Of 290 patients evaluated, the change in T stage nomenclature impacted 13 (4.5%) who were previously categorized as T3; 61 had large vessel involvement but were already T4 based on invasion of adjacent organs. The restriction of stage IV to patients with distant metastases downstaged 41 (14.1%; T4N0M0 or T3–4N1M0) to stage III. In the 7th edition, the hazard ratio (HR) for death was similar between patients with stage II and III disease, with 5-year OS 66.7%, 54.4%, 57.2%, and 14.0% (stages I, II, III, and IV, respectively). In the 8th edition, stages I and II remain unchanged, with 5-year OS for stage III and IV 44.1% and 9.2%, respectively. The c-index for the 7th and 8th editions was similar (83.4 and 82.7, respectively).

Conclusions

While 8th edition changes impact a relatively small proportion of ACC patients, they represent progress toward a common staging system that accurately reflects prognosis. In the 8th edition, the inclusion of patients with T4 tumors or nodal disease as stage III rather than IV results in improved stratification between stages II and III.

Notes

Funding

This work is not supported by a specific funding source.

Compliance with ethical standards

Conflict of interest

The authors have no financial disclosures or competing interests.

References

  1. 1.
    Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130–3136CrossRefGoogle Scholar
  2. 2.
    Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab 98:4551–4564CrossRefGoogle Scholar
  3. 3.
    Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680CrossRefGoogle Scholar
  4. 4.
    Lughezzani G, Sun M, Perrotte P et al (2010) The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46:713–719 (Oxford, England: 1990) CrossRefGoogle Scholar
  5. 5.
    Poorman CE, Ethun CG, Postlewait LM et al (2018) A novel T-stage classification system for adrenocortical carcinoma: proposal from the US Adrenocortical Carcinoma Study Group. Ann Surg Oncol 25:520–527CrossRefGoogle Scholar
  6. 6.
    Macfarlane DA (1958) Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155–186Google Scholar
  7. 7.
    Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243–250CrossRefGoogle Scholar
  8. 8.
    Li Y, Bian X, Ouyang J et al (2018) Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma. Cancer Manag Res 10:6949–6959CrossRefGoogle Scholar
  9. 9.
    Tella SH, Kommalapati A, Yaturu S et al (2018) Predictors of survival in Adrenocortical Carcinoma: an analysis from the National Cancer Database (NCDB). J Clin Endocrinol Metab 103:3566–3573CrossRefGoogle Scholar
  10. 10.
    Wang S, Chen SS, Gao WC et al (2017) Prognostic factors of adrenocortical carcinoma: an analysis of the surveillance epidemiology and end results (SEER) database. Asian Pac J Cancer Preven APJCP 18:2817–2823Google Scholar
  11. 11.
    Else T, Williams AR, Sabolch A et al (2014) Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 99:455–461CrossRefGoogle Scholar
  12. 12.
    Scollo C, Russo M, Trovato MA et al (2016) Prognostic factors for adrenocortical carcinoma outcomes. Front Endocrinol 7:99CrossRefGoogle Scholar
  13. 13.
    Vanbrugghe C, Lowery AJ, Golffier C et al (2016) Adrenocortical carcinoma surgery-surgical extent and approach. Langenbeck’s Arch Surg 401:991–997CrossRefGoogle Scholar
  14. 14.
    Asare EA, Wang TS, Winchester DP et al (2014) A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery 156:1378–1385 (discussion 1385–1376) CrossRefGoogle Scholar
  15. 15.
    Xiao WJ, Zhu Y, Dai B et al (2015) Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry. Oncotarget 6:44955–44962Google Scholar
  16. 16.
    Berruti A, Fassnacht M, Haak H et al (2014) Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 65:832–838CrossRefGoogle Scholar
  17. 17.
    Kim Y, Margonis GA, Prescott JD et al (2016) Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA surgery 151:365–373CrossRefGoogle Scholar
  18. 18.
    Libe R, Borget I, Ronchi CL et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 26:2119–2125CrossRefGoogle Scholar
  19. 19.
    Margonis GA, Kim Y, Tran TB et al (2016) Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg 211:1106–1113CrossRefGoogle Scholar
  20. 20.
    Tran TB, Postlewait LM, Maithel SK et al (2016) Actual 10-year survivors following resection of adrenocortical carcinoma. J Surg Oncol 114:971–976CrossRefGoogle Scholar
  21. 21.
    Livhits M, Li N, Yeh MW et al (2014) Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery 156:1531–1540 (discussion 1540–1531) CrossRefGoogle Scholar
  22. 22.
    Wu K, Liu Z, Liang J et al (2018) Laparoscopic versus open adrenalectomy for localized (stage 1/2) adrenocortical carcinoma: experience at a single, high-volumecenter. Surgery 164:1325–1329CrossRefGoogle Scholar
  23. 23.
    Zheng GY, Li HZ, Deng JH et al (2018) Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis. OncoTargets Ther 11:1625–1632CrossRefGoogle Scholar
  24. 24.
    Simon G, Pattou F, Mirallie E et al (2017) Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study. Surgery 161:249–256CrossRefGoogle Scholar
  25. 25.
    Poorman CE, Postlewait LM, Ethun CG et al (2017) Blood transfusion and survival for resected adrenocortical carcinoma: a study from the United States Adrenocortical Carcinoma Group. The American surgeon 83:761–768Google Scholar
  26. 26.
    Beuschlein F, Weigel J, Saeger W et al (2015) Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100:841–849CrossRefGoogle Scholar
  27. 27.
    Choi YM, Kwon H, Jeon MJ et al (2016) Clinicopathological features associated with the prognosis of patients with adrenal cortical carcinoma: usefulness of the Ki-67 index. Medicine 95:e3736CrossRefGoogle Scholar
  28. 28.
    Duregon E, Cappellesso R, Maffeis V et al (2017) Validation of the prognostic role of the “Helsinki Score” in 225 cases of adrenocortical carcinoma. Hum Pathol 62:1–7CrossRefGoogle Scholar
  29. 29.
    Pennanen M, Heiskanen I, Sane T et al (2015) Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol 46:404–410CrossRefGoogle Scholar
  30. 30.
    Anderson KL Jr, Adam MA, Thomas SM et al (2018) Impact of micro- and macroscopically positive surgical margins on survival after resection of adrenocortical carcinoma. Ann Surg Oncol 25:1425–1431CrossRefGoogle Scholar
  31. 31.
    Margonis GA, Kim Y, Prescott JD et al (2016) Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol 23:134–141CrossRefGoogle Scholar
  32. 32.
    Berruti A, Grisanti S, Pulzer A et al (2017) Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab 102:1358–1365CrossRefGoogle Scholar
  33. 33.
    Nelson DW, Chang SC, Bandera BC et al (2018) Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma. Ann Surg Oncol 25:2060–2066CrossRefGoogle Scholar
  34. 34.
    Viani GA, Viana BS (2019) Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: a systematic review of observational studies and meta-analysis. J Cancer Res Ther 15:S20–s26CrossRefGoogle Scholar
  35. 35.
    Kim Y, Margonis GA, Prescott JD et al (2017) Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability. Ann Surg 265:197–204CrossRefGoogle Scholar
  36. 36.
    Glenn JA, Else T, Hughes DT et al (2019) Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery 165:186–195CrossRefGoogle Scholar
  37. 37.
    Zheng S, Cherniack AD, Dewal N et al (2016) Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29:723–736CrossRefGoogle Scholar
  38. 38.
    Ayala-Ramirez M, Jasim S, Feng L et al (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169:891–899CrossRefGoogle Scholar
  39. 39.
    Harris EI, Lewin DN, Wang HL et al (2008) Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol 32:1816–1821CrossRefGoogle Scholar
  40. 40.
    Alanee S, Dynda D, Holland B (2015) Prevalence and prognostic value of lymph node dissection in treating adrenocortical carcinoma: a national experience. Anticancer Res 35:5575–5579Google Scholar
  41. 41.
    Nilubol N, Patel D, Kebebew E (2016) Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? A population-based study. World J Surg 40:697–705.  https://doi.org/10.1007/s00268-015-3283-2 CrossRefGoogle Scholar
  42. 42.
    Gerry JM, Tran TB, Postlewait LM et al (2016) Lymphadenectomy for adrenocortical carcinoma: Is there a therapeutic benefit? Ann Surg Oncol 23:708–713CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • Sarah B. Fisher
    • 1
  • Mouhammed A. Habra
    • 2
  • Yi-Ju Chiang
    • 1
  • Si-Yuan Wu
    • 1
  • Paul H. Graham
    • 1
  • Elizabeth G. Grubbs
    • 1
  • Jeffrey E. Lee
    • 1
  • Nancy D. Perrier
    • 1
    Email author
  1. 1.Department of Surgical Oncology, Unit 1484The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations